Updated:
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a publicly traded biotech firm developing vaccines and immunotherapies, not a family office or asset manager.
BioVaxys Technology Corp.
Antiviral and Anticancer Vaccine Platforms
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is BioVaxys Technology Corp. a family office, asset manager, or investment firm?
No. BioVaxys is a publicly traded biotechnology company focused on developing vaccines and cancer immunotherapies. It does not manage capital for external investors, operate as a family office, or have an AUM. Its business model is R&D-based drug development.
What investment stages or instruments does BioVaxys use to raise capital?
BioVaxys raises funding through public equity offerings, warrants, private placements, and grants. It does not operate fund vehicles, make direct investments in other companies, or engage in co-investment structures.
Who leads investment decisions at BioVaxys?
BioVaxys is led by its management team and board of directors, typical of a publicly traded biotech. Specific named individuals and their roles should be referenced from the firm's own filings and public communications, as those details evolve with corporate governance changes.
Does BioVaxys have any relationship with family offices, foundations, or institutional allocators?
BioVaxys does not publicly disclose ongoing relationships with family offices. As a public company, it may count institutional investors among its shareholders, but that is a passive investment relationship, not an advisory or managed-account role.
What are the main therapeutic areas for BioVaxys?
BioVaxys' pipeline includes a COVID-19 booster vaccine candidate (BVX-0320) and immunotherapies for ovarian cancer and other cancers. The firm also explores early-stage research in other infectious diseases and oncology indications.
Where is BioVaxys headquartered?
The firm's registered and business address is not available in public domain summaries. The company trades on the Canadian Securities Exchange and the Frankfurt Stock Exchange, indicating a Canadian corporate presence.
Has BioVaxys received any regulatory approvals or generated revenue from product sales?
As of 2025, per public filings, BioVaxys has not received marketing approval for any product candidate and has not generated revenue from product sales. It is a clinical-stage biotechnology company with no approved therapies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: